Potential utility of p53 immunopositivity in differentiation of adenocarcinomas from reactive epithelial atypias of the lung

Human Pathology

Volumn 27, Issue 11, 1996, Pages 1198-1203

  Cagle, Philip T ^a   Fraire, Armando E ^b   Greenberg, S Donald ^b   Cox, Adriana ^b   Brown, Richard W ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

adenocarcinoma; immunohistochemistry; lung cancer; p53; tumor suppressor gene

Indexed keywords

PROTEIN P53;

ARTICLE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; MAJOR CLINICAL STUDY; TUMOR SUPPRESSOR GENE;

EID: 0029905630     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90315-9     Document Type: Article

References (45)

1. Cagle PT: Non-specific ("usual") interstitial pneumonia, interstitial fibrosis and the honeycomb lung, in Saldana M (ed): Pathology of Pulmonary Disease. Philadelphia, PA, Lippincott, 1994, pp 325-339
2. Cagle PT: Molecular pathology of lung cancer and its clinical relevance, in Katzenstein A-L, Churg A (eds): The Lung Current Concepts. Baltimore, MD, Williams & Wilkins, 1994, pp 134-144
3. Farmer G, Bargonetti J, Zhu H, et al: Wild-type p53 activates transcription in vitro. Nature 358:83-86, 1992
4. Picksley SM, Lane DP: The p53-MDM2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? Bioessays 15:689-690, 1993
5. Wu X, Bayle JH, Olson D, et al: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132, 1993
6. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708, 1989
7. Takahashi T, Nau MM, Chiba I, et al: p53 - a frequent target for genetic abnormalities in lung cancer. Science 246:491-494, 1989
8. Kishimoto Y, Murakami Y, Shiraishi M, et al: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52:4799-4804, 1992
9. Miller CW, Simon K, Aslo A, et al: p53 mutations in human lung tumors. Cancer Res 52:1695-1698, 1992
10. Porter PL, Gown AM, Kramp SG, et al: Widespread p53 overexpression in human malignant tumors. Am J Pathol 140:145-153, 1992
11. Soussi T, Legros Y, Lubin R, et al: Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1-9, 1994
12. Hall PA, Ray A, Lemoine NR, et al: p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 338:513, 1991 (letter)
13. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992
14. Battifora H: p53 immunohistochemistry: A word of caution. HUM PATHOL 25:435-437, 1994
15. Carbone DP, Mitsudomi T, Chiba I, et al: p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871. Chest 106:3775-3818, 1994
16. Hall PA, Lane DP: p53 in tumor pathology: Can we trust immunohistochemistry? Revisited! J Pathol 172:1-4, 1994
17. Hurlimann J, Chaubert P, Benhattar J: p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: Correlation between immunohistochemical and molecular biology techniques. Mod Pathol 7:423-428, 1994
18. Dei Tos AP, Doglioni C, Laurino L, et al: p53 protein expression in non-neoplastic and benign and malignant neoplasm of soft tissue. Histopathology 22:45-50, 1993
19. Cagle PT, Brown RW, Lebovitz RM: p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. HUM PATHOL 25:443-448, 1994
20. Walts AE, Said JW, Koeffler HP: Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells. Mod Pathol 7:462-468, 1994
21. Younes M, Lebovitz RM, Bommer KE, et al: p53 accumulation in benign breast biopsy specimens. HUM PATHOL 26:155-158, 1995
22. Bartek J, Bartkova J, Lukas J, et al: Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169:27-34, 1993
23. Linden MD, Nathanson SD, Zarbo RJ: Evaluation of anti-p53 antibody staining: Quality control and technical considerations. Appl Immunohistochem 2:218-224, 1994
24. Tenaud C, Negoescu A, Labat-Moleur F, et al: p53 immunolabeling in archival paraffin-embedded tissues: Optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 7:853-859, 1994
25. Brown RW, Chirala R: Utility of microwave-citrate antigen retrieval in diagnostic immunohistochemistry. Mod Pathol 8:515-520, 1995
26. Kafiri G, Thomas DM, Shepherd NA, et al: p53 expression is common in malignant mesothelioma. Histopathology 21:331-334, 1992
27. Mayall FG, Goddard H, Gibbs AR: p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 168:377-381, 1992
28. Ramael M, Lemmens G, Veerdekens C, et al: Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168:371-375, 1992
29. Ledet SC, Brown RW, Cagle PT: p53 immunostaining in the differentiation of inflammatory pseudotumor from sarcoma involving the lung. Mod Pathol 8:282-286, 1995
30. van den Heuvel SJ, van Laar T, Kast WM, et al: Association between cellular p53 and the adenovirus 5 eib-55kd proteins reduces the oncogenicity of AD-transformed cells. EMBO J 9:2621-2629, 1990
31. Ciechanover A, DiGiuseppe JA, Berchovic B, et al: Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A 88:139-143, 1991
32. Ronen D, Rotter V, Reisman D: Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif. Proc Natl Acad Sci U S A 88:4128-4132, 1991
33. Muganda P, Mendoza O, Hernandez J, et al: Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. J Virol 68:8028-8034, 1994
34. Meyer EC, Liebow AA: Relationship of interstitial pneumonia, honeycombing and atypical proliferation to cancer of the lung. Cancer 18:322-351, 1965
35. Fraire AE, Greenberg SD, O'Neal RM, et al: Diffuse interstitial fibrosis of the lung. Am J Clin Pathol 59:636-647, 1973
36. Turner-Warwick M, Lebowitz M, Burrows B, et al: Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35:496-499, 1980
37. Peters-Golden M, Wise RA, Hochberg M, et al: Incidence of lung cancer in systemic sclerosis. J Rheumatol 12:1136-1139, 1985
38. Shimosato Y, Noguchi M, Matsuno Y: Adenocarcinoma of the lung: Its development and malignant progression. Lung Cancer 9:99-108, 1993
39. Miller RR, Nelems B, Evans KG, et al: Glandular neoplasia of the lung: A proposed analogy to colonie tumors. Cancer 61:1009-1014, 1988
40. Kerr KM, Carey Fa, King G, et al: Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53 and c-erbB-2 expression. J Pathol 174:249-256, 1994
41. Kitamura H, Kameda Y, Nakamura N, et al: Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol 146:876-887, 1995
42. Rao SK, Fraire AE: Alveolar cell hyperplasia in association with adenocarcinoma of lung. Mod Pathol 8:165-169, 1995
43. Suzuki H, Takahashi T, Kuroishi T, et al: p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res 52:734-736, 1992
44. Westra WH, Offerhaus JA, Goodman SN, et al: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 17:213-220, 1993
45. Cagle PT: Tumors of the lung (excluding lymphoid tumors), in Thurlbeck WM, Churg AM (eds): Pathology of the Lung, (ed 2). New York, NY, Thieme, 1995, pp 437-551